Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Drugs and Therapy
Published in: Cardiovascular Drugs and Therapy 3/2021

01-06-2021 | Invited Review Article

Integration of Transformative Platforms for the Discovery of Causative Genes in Cardiovascular Diseases

Authors: Haocheng Lu, Jifeng Zhang, Y. Eugene Chen, Minerva T. Garcia-Barrio

Published in: Cardiovascular Drugs and Therapy | Issue 3/2021

Login to get access

Abstract

Cardiovascular diseases are the leading cause of morbidity and mortality worldwide. Genome-wide association studies (GWAS) are powerful epidemiological tools to find genes and variants associated with cardiovascular diseases while follow-up biological studies allow to better understand the etiology and mechanisms of disease and assign causality. Improved methodologies and reduced costs have allowed wider use of bulk and single-cell RNA sequencing, human-induced pluripotent stem cells, organoids, metabolomics, epigenomics, and novel animal models in conjunction with GWAS. In this review, we feature recent advancements relevant to cardiovascular diseases arising from the integration of genetic findings with multiple enabling technologies within multidisciplinary teams to highlight the solidifying transformative potential of this approach. Well-designed workflows integrating different platforms are greatly improving and accelerating the unraveling and understanding of complex disease processes while promoting an effective way to find better drug targets, improve drug design and repurposing, and provide insight towards a more personalized clinical practice.
Literature
1.
Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–596.PubMedCrossRef
2.
Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–e528.PubMedCrossRef
3.
Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860–921.PubMedCrossRef
4.
Shearman AM, Ordovas JM, Cupples LA, Schaefer EJ, Harmon MD, Shao Y, et al. Evidence for a gene influencing the TG/HDL-C ratio on chromosome 7q32.3-qter: a genome-wide scan in the Framingham study. Hum Mol Genet. 2000;9(9):1315–20.PubMedCrossRef
5.
Elbein SC, Hasstedt SJ. Quantitative trait linkage analysis of lipid-related traits in familial type 2 diabetes: evidence for linkage of triglyceride levels to chromosome 19q. Diabetes. 2002;51(2):528–35.PubMedCrossRef
6.
Malhotra A, Wolford JK. American Diabetes Association GSG. Analysis of quantitative lipid traits in the genetics of NIDDM (GENNID) study. Diabetes. 2005;54(10):3007–14.PubMedCrossRef
7.
Tam V, Patel N, Turcotte M, Bosse Y, Pare G, Meyre D. Benefits and limitations of genome-wide association studies. Nat Rev Genet. 2019;20(8):467–84.PubMedCrossRef
8.
Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 2008;5(7):621–8.PubMedCrossRef
9.
Xu Q, Modrek B, Lee C. Genome-wide detection of tissue-specific alternative splicing in the human transcriptome. Nucleic Acids Res. 2002;30(17):3754–66.PubMedPubMedCentralCrossRef
10.
Cloonan N, Forrest AR, Kolle G, Gardiner BB, Faulkner GJ, Brown MK, et al. Stem cell transcriptome profiling via massive-scale mRNA sequencing. Nat Methods. 2008;5(7):613–9.PubMedCrossRef
11.
Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995;270(5235):467–70.PubMedCrossRef
12.
Marioni JC, Mason CE, Mane SM, Stephens M, Gilad Y. RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome Res. 2008;18(9):1509–17.PubMedPubMedCentralCrossRef
13.
Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. Science. 1995;270(5235):484–7.PubMedCrossRef
14.
Stark R, Grzelak M, Hadfield J. RNA sequencing: the teenage years. Nat Rev Genet. 2019;20(11):631–56.PubMedCrossRef
15.
Heap GA, Yang JH, Downes K, Healy BC, Hunt KA, Bockett N, et al. Genome-wide analysis of allelic expression imbalance in human primary cells by high-throughput transcriptome resequencing. Hum Mol Genet. 2010;19(1):122–34.PubMedCrossRef
16.
Alloza I, Salegi A, Mena J, Navarro RT, Martin C, Aspichueta P, et al. BIRC6 is associated with vulnerability of carotid atherosclerotic plaque. Int J Mol Sci. 2020;21(24):9387.PubMedCentralCrossRef
17.
Nielsen JB, Rom O, Surakka I, Graham SE, Zhou W, Roychowdhury T, et al. Loss-of-function genomic variants highlight potential therapeutic targets for cardiovascular disease. Nat Commun. 2020;11(1):6417.PubMedPubMedCentralCrossRef
18.
Lescroart F, Wang X, Lin X, Swedlund B, Gargouri S, Sanchez-Danes A, et al. Defining the earliest step of cardiovascular lineage segregation by single-cell RNA-seq. Science. 2018;359(6380):1177–81.PubMedPubMedCentralCrossRef
19.
Lu D, Thum T. RNA-based diagnostic and therapeutic strategies for cardiovascular disease. Nat Rev Cardiol. 2019;16(11):661–74.PubMedCrossRef
20.
21.
Natarajan KN, Miao Z, Jiang M, Huang X, Zhou H, Xie J, et al. Comparative analysis of sequencing technologies for single-cell transcriptomics. Genome Biol. 2019;20(1):70.PubMedPubMedCentralCrossRef
22.
Alencar GF, Owsiany KM, Karnewar S, Sukhavasi K, Mocci G, Nguyen AT, et al. Stem cell pluripotency genes Klf4 and Oct4 regulate complex SMC phenotypic changes critical in late-stage atherosclerotic lesion pathogenesis. Circulation. 2020;142(21):2045–59.PubMedPubMedCentralCrossRef
23.
24.
Winkels H, Ehinger E, Vassallo M, Buscher K, Dinh HQ, Kobiyama K, et al. Atlas of the immune cell repertoire in mouse atherosclerosis defined by single-cell RNA-sequencing and mass cytometry. Circ Res. 2018;122(12):1675–88.PubMedPubMedCentralCrossRef
25.
Wirka RC, Wagh D, Paik DT, Pjanic M, Nguyen T, Miller CL, et al. Atheroprotective roles of smooth muscle cell phenotypic modulation and the TCF21 disease gene as revealed by single-cell analysis. Nat Med. 2019;25(8):1280–9.PubMedPubMedCentralCrossRef
26.
Kim K, Shim D, Lee JS, Zaitsev K, Williams JW, Kim KW, et al. Transcriptome analysis reveals nonfoamy rather than foamy plaque macrophages are proinflammatory in atherosclerotic murine models. Circ Res. 2018;123(10):1127–42.PubMedPubMedCentralCrossRef
27.
Xiong X, Kuang H, Ansari S, Liu T, Gong J, Wang S, et al. Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis. Mol Cell. 2019;75(3):644–60 e5.PubMedPubMedCentralCrossRef
28.
Jaitin DA, Adlung L, Thaiss CA, Weiner A, Li B, Descamps H, et al. Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner. Cell. 2019;178(3):686–98 e14.PubMedPubMedCentralCrossRef
29.
Ramachandran P, Dobie R, Wilson-Kanamori JR, Dora EF, Henderson BEP, Luu NT, et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature. 2019;575(7783):512–8.PubMedPubMedCentralCrossRef
30.
Depuydt MAC, Prange KHM, Slenders L, Ord T, Elbersen D, Boltjes A, et al. Microanatomy of the human atherosclerotic plaque by single-cell transcriptomics. Circ Res. 2020;127(11):1437–55.PubMedPubMedCentralCrossRef
31.
Patel D, Mez J, Vardarajan BN, Staley L, Chung J, Zhang X, et al. Association of rare coding mutations with Alzheimer disease and other dementias among adults of European ancestry. JAMA Netw Open. 2019;2(3):e191350.PubMedPubMedCentralCrossRef
32.
Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, et al. Fast, sensitive and accurate integration of single-cell data with harmony. Nat Methods. 2019;16(12):1289–96.PubMedPubMedCentralCrossRef
33.
Hou XH, Bi YL, Tan MS, Xu W, Li JQ, Shen XN, et al. Genome-wide association study identifies Alzheimer’s risk variant in MS4A6A influencing cerebrospinal fluid sTREM2 levels. Neurobiol Aging. 2019;84:241 e13–20.CrossRef
34.
Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease. Nat Genet. 2017;49(9):1373–84.PubMedPubMedCentralCrossRef
35.
Reiner AP, Beleza S, Franceschini N, Auer PL, Robinson JG, Kooperberg C, et al. Genome-wide association and population genetic analysis of C-reactive protein in African American and Hispanic American women. Am J Hum Genet. 2012;91(3):502–12.PubMedPubMedCentralCrossRef
36.
Li R, Guan J, Zhou S. Single-cell RNA-seq data clustering: a survey with performance comparison study. J Bioinforma Comput Biol. 2020;18(4):2040005.CrossRef
37.
Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM 3rd, et al. Comprehensive integration of single-cell data. Cell. 2019;177(7):1888–902 e21.PubMedPubMedCentralCrossRef
38.
Haghverdi L, Lun ATL, Morgan MD, Marioni JC. Batch effects in single-cell RNA-sequencing data are corrected by matching mutual nearest neighbors. Nat Biotechnol. 2018;36(5):421–7.PubMedPubMedCentralCrossRef
39.
Liu J, Gao C, Sodicoff J, Kozareva V, Macosko EZ, Welch JD. Jointly defining cell types from multiple single-cell datasets using LIGER. Nat Protoc. 2020;15(11):3632–62.PubMedPubMedCentralCrossRef
40.
Tran HTN, Ang KS, Chevrier M, Zhang X, Lee NYS, Goh M, et al. A benchmark of batch-effect correction methods for single-cell RNA sequencing data. Genome Biol. 2020;21(1):12.PubMedPubMedCentralCrossRef
41.
Liao J, Lu X, Shao X, Zhu L, Fan X. Uncovering an organ’s molecular architecture at single-cell resolution by spatially resolved transcriptomics. Trends Biotechnol. 2021;39(1):43–58.PubMedCrossRef
42.
Nichterwitz S, Chen G, Aguila Benitez J, Yilmaz M, Storvall H, Cao M, et al. Laser capture microscopy coupled with Smart-seq2 for precise spatial transcriptomic profiling. Nat Commun. 2016;7(1):12139.PubMedPubMedCentralCrossRef
43.
Eng CL, Lawson M, Zhu Q, Dries R, Koulena N, Takei Y, et al. Transcriptome-scale super-resolved imaging in tissues by RNA seqFISH. Nature. 2019;568(7751):235–9.PubMedPubMedCentralCrossRef
44.
Xia C, Fan J, Emanuel G, Hao J, Zhuang X. Spatial transcriptome profiling by MERFISH reveals subcellular RNA compartmentalization and cell cycle-dependent gene expression. Proc Natl Acad Sci U S A. 2019;116(39):19490–9.PubMedPubMedCentralCrossRef
45.
Rodriques SG, Stickels RR, Goeva A, Martin CA, Murray E, Vanderburg CR, et al. Slide-seq: a scalable technology for measuring genome-wide expression at high spatial resolution. Science. 2019;363(6434):1463–7.PubMedPubMedCentralCrossRef
46.
Liu Y, Yang M, Deng Y, Su G, Enninful A, Guo CC, et al. High-spatial-resolution multi-omics sequencing via deterministic barcoding in tissue. Cell. 2020;183(6):1665–81 e18.PubMedPubMedCentralCrossRef
47.
Asp M, Giacomello S, Larsson L, Wu C, Fürth D, Qian X, et al. A spatiotemporal organ-wide gene expression and cell atlas of the developing human heart. Cell. 2019;179(7):1647–60.e19.PubMedCrossRef
48.
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–72.PubMedCrossRef
49.
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–76.PubMedCrossRef
50.
Zahumenska R, Nosal V, Smolar M, Okajcekova T, Skovierova H, Strnadel J, et al. Induced pluripotency: a powerful tool for in vitro modeling. Int J Mol Sci. 2020;21(23):8910.PubMedCentralCrossRef
51.
Lee J, Sutani A, Kaneko R, Takeuchi J, Sasano T, Kohda T, et al. In vitro generation of functional murine heart organoids via FGF4 and extracellular matrix. Nat Commun. 2020;11(1):4283.PubMedPubMedCentralCrossRef
52.
53.
Gheibi S, Singh T, da Cunha J, Fex M, Mulder H. Insulin/glucose-responsive cells derived from induced pluripotent stem cells: disease modeling and treatment of diabetes. Cells. 2020;9(11):2465.PubMedCentralCrossRef
54.
Peng GY, Lin Y, Li JJ, Wang Y, Huang HY, Shen ZY. The application of induced pluripotent stem cells in pathogenesis study and gene therapy for vascular disorders: current progress and future challenges. Stem Cells Int. 2019;2019:9613258.PubMedPubMedCentralCrossRef
55.
Newman DL, Abney M, Dytch H, Parry R, McPeek MS, Ober C. Major loci influencing serum triglyceride levels on 2q14 and 9p21 localized by homozygosity-by-descent mapping in a large Hutterite pedigree. Hum Mol Genet. 2003;12(2):137–44.PubMedCrossRef
56.
Bell RD, Long X, Lin M, Bergmann JH, Nanda V, Cowan SL, et al. Identification and initial functional characterization of a human vascular cell-enriched long noncoding RNA. Arterioscler Thromb Vasc Biol. 2014;34(6):1249–59.PubMedPubMedCentralCrossRef
57.
Lo Sardo V, Chubukov P, Ferguson W, Kumar A, Teng EL, Duran M, et al. Unveiling the role of the most impactful cardiovascular risk locus through haplotype editing. Cell. 2018;175(7):1796–810.e20.PubMedCrossRef
58.
Panopoulos AD, D’Antonio M, Benaglio P, Williams R, Hashem SI, Schuldt BM, et al. iPSCORE: A resource of 222 iPSC lines enabling functional characterization of genetic variation across a variety of cell types. Stem Cell Rep. 2017;8(4):1086–100.CrossRef
59.
Mirauta BA, Seaton DD, Bensaddek D, Brenes A, Bonder MJ, Kilpinen H, et al. Population-scale proteome variation in human induced pluripotent stem cells. Elife. 2020;9:e57390.PubMedPubMedCentralCrossRef
60.
Kilpinen H, Goncalves A, Leha A, Afzal V, Alasoo K, Ashford S, et al. Common genetic variation drives molecular heterogeneity in human iPSCs. Nature. 2017;546(7658):370–5.PubMedPubMedCentralCrossRef
61.
Abou-Saleh H, Zouein FA, El-Yazbi A, Sanoudou D, Raynaud C, Rao C, et al. The march of pluripotent stem cells in cardiovascular regenerative medicine. Stem Cell Res Ther. 2018;9(1):201.PubMedPubMedCentralCrossRef
62.
Hirai H, Yang B, Garcia-Barrio MT, Rom O, Ma PX, Zhang J, et al. Direct reprogramming of fibroblasts into smooth muscle-like cells with defined transcription factors-brief report. Arterioscler Thromb Vasc Biol. 2018;38(9):2191–7.PubMedPubMedCentralCrossRef
63.
Chang Y, Cho B, Kim S, Kim J. Direct conversion of fibroblasts to osteoblasts as a novel strategy for bone regeneration in elderly individuals. Exp Mol Med. 2019;51(5):1–8.PubMedCrossRef
64.
Davis RL, Weintraub H, Lassar AB. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell. 1987;51(6):987–1000.PubMedCrossRef
65.
Cochrane A, Albers HJ, Passier R, Mummery CL, van den Berg A, Orlova VV, et al. Advanced in vitro models of vascular biology: human induced pluripotent stem cells and organ-on-chip technology. Adv Drug Deliv Rev. 2019;140:68–77.PubMedCrossRef
66.
Davaapil H, Shetty DK, Sinha S. Aortic “Disease-in-a-Dish”: mechanistic insights and drug development using iPSC-based disease modeling. Front Cell Dev Biol. 2020;8:550504.PubMedPubMedCentralCrossRef
67.
Cooper SE, Schwartzentruber J, Bello E, Coomber EL, Bassett AR. Screening for functional transcriptional and splicing regulatory variants with GenIE. Nucleic Acids Res. 2020;48(22):e131.PubMedPubMedCentralCrossRef
68.
Tuveson D, Clevers H. Cancer modeling meets human organoid technology. Science. 2019;364(6444):952–5.PubMedCrossRef
69.
Bergeron N, Phan BA, Ding Y, Fong A, Krauss RM. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Circulation. 2015;132(17):1648–66.PubMedCrossRef
70.
71.
Prior N, Inacio P, Huch M. Liver organoids: from basic research to therapeutic applications. Gut. 2019;68(12):2228–37.PubMedCrossRef
72.
Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature. 2013;499(7459):481–4.PubMedCrossRef
73.
Hu W, Lu H, Zhang J, Fan Y, Chang Z, Liang W, et al. Kruppel-like factor 14, a coronary artery disease associated transcription factor, inhibits endothelial inflammation via NF-kappaB signaling pathway. Atherosclerosis. 2018;278:39–48.PubMedPubMedCentralCrossRef
74.
Wu F, Wu D, Ren Y, Huang Y, Feng B, Zhao N, et al. Generation of hepatobiliary organoids from human induced pluripotent stem cells. J Hepatol. 2019;70(6):1145–58.PubMedCrossRef
75.
Nantasanti S, Spee B, Kruitwagen HS, Chen C, Geijsen N, Oosterhoff LA, et al. Disease modeling and gene therapy of copper storage disease in canine hepatic organoids. Stem Cell Rep. 2015;5(5):895–907.CrossRef
76.
Andersson ER, Chivukula IV, Hankeova S, Sjöqvist M, Tsoi YL, Ramsköld D, et al. Mouse model of Alagille syndrome and mechanisms of jagged1 missense mutations. Gastroenterology. 2018;154(4):1080–95.PubMedCrossRef
77.
Abbey D, Elwyn S, Hand NJ, Musunuru K, Rader DJ. Self-organizing human induced pluripotent stem cell hepatocyte 3D organoids inform the biology of the pleiotropic TRIB1 gene. Hepatol Commun. 2020;4(9):1316–31.PubMedPubMedCentralCrossRef
78.
Richards DJ, Li Y, Kerr CM, Yao J, Beeson GC, Coyle RC, et al. Human cardiac organoids for the modelling of myocardial infarction and drug cardiotoxicity. Nat Biomed Eng. 2020;4(4):446–62.PubMedPubMedCentralCrossRef
79.
Giacomelli E, Bellin M, Orlova VV, Mummery CL. Co-differentiation of human pluripotent stem cells-derived cardiomyocytes and endothelial cells from cardiac mesoderm provides a three-dimensional model of cardiac microtissue. Curr Protoc Hum Genet. 2017;95:21 9 1–2.
80.
Zhang YS, Arneri A, Bersini S, Shin SR, Zhu K, Goli-Malekabadi Z, et al. Bioprinting 3D microfibrous scaffolds for engineering endothelialized myocardium and heart-on-a-chip. Biomaterials. 2016;110:45–59.PubMedPubMedCentralCrossRef
81.
Skardal A, Murphy SV, Devarasetty M, Mead I, Kang HW, Seol YJ, et al. Multi-tissue interactions in an integrated three-tissue organ-on-a-chip platform. Sci Rep. 2017;7(1):8837.PubMedPubMedCentralCrossRef
82.
Protze SI, Lee JH, Keller GM. Human pluripotent stem cell-derived cardiovascular cells: from developmental biology to therapeutic applications. Cell Stem Cell. 2019;25(3):311–27.PubMedCrossRef
83.
Lee EJ, Kim DE, Azeloglu EU, Costa KD. Engineered cardiac organoid chambers: toward a functional biological model ventricle. Tissue Eng Part A. 2008;14(2):215–25.PubMedCrossRef
84.
Zhao Y, Rafatian N, Feric NT, Cox BJ, Aschar-Sobbi R, Wang EY, et al. A platform for generation of chamber-specific cardiac tissues and disease modeling. Cell. 2019;176(4):913–27 e18.PubMedPubMedCentralCrossRef
85.
Skardal A, Aleman J, Forsythe S, Rajan S, Murphy S, Devarasetty M, et al. Drug compound screening in single and integrated multi-organoid body-on-a-chip systems. Biofabrication. 2020;12(2):025017.PubMedCrossRef
86.
Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121(7):749–70.PubMedPubMedCentralCrossRef
87.
van der Harst P, van Setten J, Verweij N, Vogler G, Franke L, Maurano MT, et al. 52 genetic loci influencing myocardial mass. J Am Coll Cardiol. 2016;68(13):1435–48.PubMedPubMedCentralCrossRef
88.
Prondzynski M, Lemoine MD, Zech AT, Horvath A, Di Mauro V, Koivumaki JT, et al. Disease modeling of a mutation in alpha-actinin 2 guides clinical therapy in hypertrophic cardiomyopathy. EMBO Mol Med. 2019;11(12):e11115.PubMedPubMedCentralCrossRef
89.
Hendriks D, Clevers H, Artegiani B. CRISPR-Cas tools and their application in genetic engineering of human stem cells and organoids. Cell Stem Cell. 2020;27(5):705–31.PubMedCrossRef
90.
Bender R, McCarthy M, Brown T, Bukowska J, Smith S, Abbott RD, et al. Human adipose derived cells in two- and three-dimensional cultures: functional validation of an in vitro fat construct. Stem Cells Int. 2020;2020:4242130.PubMedPubMedCentralCrossRef
91.
Liu C, Niu K, Xiao Q. Updated perspectives on vascular cell specification and pluripotent stem cell-derived vascular organoids for studying vasculopathies. Cardiovasc Res. 2020:cvaa313.
92.
Wimmer RA, Leopoldi A, Aichinger M, Kerjaschki D, Penninger JM. Generation of blood vessel organoids from human pluripotent stem cells. Nat Protoc. 2019;14(11):3082–100.PubMedCrossRef
93.
Stein JM, Mummery CL, Bellin M. Engineered models of the human heart: directions and challenges. Stem Cell Rep. 2020:S2213-6711(20)30461-6.
94.
Chen PY, Qin L, Li G, Malagon-Lopez J, Wang Z, Bergaya S, et al. Smooth muscle cell reprogramming in aortic aneurysms. Cell Stem Cell. 2020;26(4):542–57 e11.PubMedPubMedCentralCrossRef
95.
Golledge J, Krishna SM, Wang Y. Mouse models for abdominal aortic aneurysm. Br J Pharmacol. 2020:15620.
96.
O’Brien RM. Moving on from GWAS: functional studies on the G6PC2 gene implicated in the regulation of fasting blood glucose. Curr Diab Rep. 2013;13(6):768–77.PubMedPubMedCentralCrossRef
97.
Gutierrez-Aguilar R, Kim DH, Casimir M, Dai XQ, Pfluger PT, Park J, et al. The role of the transcription factor ETV5 in insulin exocytosis. Diabetologia. 2014;57(2):383–91.PubMedCrossRef
98.
Graham LA, Padmanabhan S, Fraser NJ, Kumar S, Bates JM, Raffi HS, et al. Validation of uromodulin as a candidate gene for human essential hypertension. Hypertension. 2014;63(3):551–8.PubMedCrossRef
99.
Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466(7307):707–13.PubMedPubMedCentralCrossRef
100.
Guo Y, Fan Y, Zhang J, Lomberk GA, Zhou Z, Sun L, et al. Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production. J Clin Invest. 2015;125(10):3819–30.PubMedPubMedCentralCrossRef
101.
102.
Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111–21.PubMedPubMedCentralCrossRef
103.
Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355(6327):842–7.PubMedPubMedCentralCrossRef
104.
Fan J, Kitajima S, Watanabe T, Xu J, Zhang J, Liu E, et al. Rabbit models for the study of human atherosclerosis: from pathophysiological mechanisms to translational medicine. Pharmacol Ther. 2015;146:104–19.PubMedCrossRef
105.
106.
Zhang J, Niimi M, Yang D, Liang J, Xu J, Kimura T, et al. Deficiency of cholesteryl ester transfer protein protects against atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 2017;37(6):1068–75.PubMedPubMedCentralCrossRef
107.
108.
Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knock-out mice. J Exp Med. 1997;185(12):2043–51.PubMedPubMedCentralCrossRef
109.
Schreiweis C, Bornschein U, Burguière E, Kerimoglu C, Schreiter S, Dannemann M, et al. Humanized Foxp2 accelerates learning by enhancing transitions from declarative to procedural performance. Proc Natl Acad Sci U S A. 2014;111(39):14253–8.PubMedPubMedCentralCrossRef
110.
Reaume AG, Howland DS, Trusko SP, Savage MJ, Lang DM, Greenberg BD, et al. Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer’s disease mutations and a “humanized” Abeta sequence. J Biol Chem. 1996;271(38):23380–8.PubMedCrossRef
111.
Raffai RL, Dong LM, Farese RV Jr, Weisgraber KH. Introduction of human apolipoprotein E4 “domain interaction” into mouse apolipoprotein E. Proc Natl Acad Sci U S A. 2001;98(20):11587–91.PubMedPubMedCentralCrossRef
112.
Malloy SI, Altenburg MK, Knouff C, Lanningham-Foster L, Parks JS, Maeda N. Harmful effects of increased LDLR expression in mice with human APOE*4 but not APOE*3. Arterioscler Thromb Vasc Biol. 2004;24(1):91–7.PubMedCrossRef
113.
Sullivan PM, Mezdour H, Quarfordt SH, Maeda N. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J Clin Invest. 1998;102(1):130–5.PubMedPubMedCentralCrossRef
114.
Knouff C, Hinsdale ME, Mezdour H, Altenburg MK, Watanabe M, Quarfordt SH, et al. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest. 1999;103(11):1579–86.PubMedPubMedCentralCrossRef
115.
Jiang XC, Masucci-Magoulas L, Mar J, Lin M, Walsh A, Breslow JL, et al. Down-regulation of mRNA for the low density lipoprotein receptor in transgenic mice containing the gene for human cholesteryl ester transfer protein. Mechanism to explain accumulation of lipoprotein B particles. J Biol Chem. 1993;268(36):27406–12.PubMedCrossRef
116.
Luo JL, Yang Q, Tong WM, Hergenhahn M, Wang ZQ, Hollstein M. Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene. 2001;20(3):320–8.PubMedCrossRef
117.
Menalled LB, Kudwa AE, Miller S, Fitzpatrick J, Watson-Johnson J, Keating N, et al. Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington’s disease: zQ175. PLoS One. 2012;7(12):e49838.PubMedPubMedCentralCrossRef
118.
Schmouth JF, Bonaguro RJ, Corso-Diaz X, Simpson EM. Modelling human regulatory variation in mouse: finding the function in genome-wide association studies and whole-genome sequencing. PLoS Genet. 2012;8(3):e1002544.PubMedPubMedCentralCrossRef
119.
Gawenis LR, Hodges CA, McHugh DR, Valerio DM, Miron A, Cotton CU, et al. A BAC transgene expressing human CFTR under control of its regulatory elements rescues Cftr knockout mice. Sci Rep. 2019;9(1):11828.PubMedPubMedCentralCrossRef
120.
Taguchi T, Ikuno M, Hondo M, Parajuli LK, Taguchi K, Ueda J, et al. alpha-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson’s disease model. Brain. 2020;143(1):249–65.PubMedCrossRef
121.
Tian X, Richard A, El-Saadi MW, Bhandari A, Latimer B, Van Savage I, et al. Dosage sensitivity intolerance of VIPR2 microduplication is disease causative to manifest schizophrenia-like phenotypes in a novel BAC transgenic mouse model. Mol Psychiatry. 2019;24(12):1884–901.PubMedCrossRef
122.
Cubria MB, Suarez S, Masoudi A, Oftadeh R, Kamalapathy P, DuBose A, et al. Evaluation of musculoskeletal phenotype of the G608G progeria mouse model with lonafarnib, pravastatin, and zoledronic acid as treatment groups. Proc Natl Acad Sci U S A. 2020;117(22):12029–40.PubMedPubMedCentralCrossRef
123.
Dash PK, Alomar FA, Hackfort BT, Su H, Conaway A, Poluektova LY, et al. HIV-1-associated left ventricular cardiac dysfunction in humanized mice. Sci Rep. 2020;10(1):9746.PubMedPubMedCentralCrossRef
124.
Xu J, Livraghi-Butrico A, Hou X, Rajagopalan C, Zhang J, Song J, et al. Phenotypes of CF rabbits generated by CRISPR/Cas9-mediated disruption of the CFTR gene. JCI Insight. 2020;6(1):e139813.CrossRef
125.
Suemizu H, Hasegawa M, Kawai K, Taniguchi K, Monnai M, Wakui M, et al. Establishment of a humanized model of liver using NOD/Shi-scid IL2Rgnull mice. Biochem Biophys Res Commun. 2008;377(1):248–52.PubMedCrossRef
126.
Hasegawa M, Kawai K, Mitsui T, Taniguchi K, Monnai M, Wakui M, et al. The reconstituted ‘humanized liver’ in TK-NOG mice is mature and functional. Biochem Biophys Res Commun. 2011;405(3):405–10.PubMedPubMedCentralCrossRef
127.
Jiang C, Li P, Ruan X, Ma Y, Kawai K, Suemizu H, et al. Comparative transcriptomics analyses in livers of mice, humans, and humanized mice define human-specific gene networks. Cells. 2020;9(12):2566.PubMedCentralCrossRef
128.
Seifuddin F, Singh K, Suresh A, Judy JT, Chen YC, Chaitankar V, et al. lncRNAKB, a knowledgebase of tissue-specific functional annotation and trait association of long noncoding RNA. Sci Data. 2020;7(1):326.PubMedPubMedCentralCrossRef
129.
Sugahara G, Yamasaki C, Yanagi A, Furukawa S, Ogawa Y, Fukuda A, et al. Humanized liver mouse model with transplanted human hepatocytes from patients with ornithine transcarbamylase deficiency. J Inherit Metab Dis. 2020:12347.
130.
Sari G, Meester EJ, van der Zee LC, Wouters K, van Lennep JR, Peppelenbosch M, et al. A mouse model of humanized liver shows a human-like lipid profile, but does not form atherosclerotic plaque after western type diet. Biochem Biophys Res Commun. 2020;524(2):510–5.PubMedCrossRef
131.
Watanabe Y, Ito T, Saeki M, Kuroda M, Tanzawa K, Mochizuki M, et al. Hypolipidemic effects of CS-500 (ML-236B) in WHHL-rabbit, a heritable animal model for hyperlipidemia. Atherosclerosis. 1981;38(1-2):27–31.PubMedCrossRef
132.
Shiomi M, Koike T, Ito T. Contribution of the WHHL rabbit, an animal model of familial hypercholesterolemia, to elucidation of the anti-atherosclerotic effects of statins. Atherosclerosis. 2013;231(1):39–47.PubMedCrossRef
133.
Shiomi M, Ito T, Yamada S, Kawashima S, Fan J. Development of an animal model for spontaneous myocardial infarction (WHHLMI rabbit). Arterioscler Thromb Vasc Biol. 2003;23(7):1239–44.PubMedCrossRef
134.
Niimi M, Yang D, Kitajima S, Ning B, Wang C, Li S, et al. ApoE knockout rabbits: a novel model for the study of human hyperlipidemia. Atherosclerosis. 2016;245:187–93.PubMedCrossRef
135.
Fan J, Shimoyamada H, Sun H, Marcovina S, Honda K, Watanabe T. Transgenic rabbits expressing human apolipoprotein(a) develop more extensive atherosclerotic lesions in response to a cholesterol-rich diet. Arterioscler Thromb Vasc Biol. 2001;21(1):88–94.PubMedCrossRef
136.
137.
138.
Freeman DJ, Packard CJ, Shepherd J, Gaffney D. Polymorphisms in the gene coding for cholesteryl ester transfer protein are related to plasma high-density lipoprotein cholesterol and transfer protein activity. Clin Sci (Lond). 1990;79(6):575–81.CrossRef
139.
Corbex M, Poirier O, Fumeron F, Betoulle D, Evans A, Ruidavets JB, et al. Extensive association analysis between the CETP gene and coronary heart disease phenotypes reveals several putative functional polymorphisms and gene-environment interaction. Genet Epidemiol. 2000;19(1):64–80.PubMedCrossRef
140.
Prasad G, Bandesh K, Giri AK, Kauser Y, Chanda P, Parekatt V, et al. Genome-wide association study of metabolic syndrome reveals primary genetic variants at CETP locus in Indians. Biomolecules. 2019;9(8):321.PubMedCentralCrossRef
141.
Park YM, Province MA, Gao X, Feitosa M, Wu J, Ma D, et al. Longitudinal trends in the association of metabolic syndrome with 550 k single-nucleotide polymorphisms in the Framingham Heart Study. BMC Proc. 2009;3(Suppl 7):S116.PubMedPubMedCentralCrossRef
142.
Moriyama Y, Okamura T, Inazu A, Doi M, Iso H, Mouri Y, et al. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev Med. 1998;27(5 Pt 1):659–67.PubMedCrossRef
143.
Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990;323(18):1234–8.PubMedCrossRef
144.
Lu Y, Liang M, Zhang Q, Liu Z, Song Y, Lai L, et al. Mutations of GADD45G in rabbits cause cleft lip by the disorder of proliferation, apoptosis and epithelial-mesenchymal transition (EMT). Biochim Biophys Acta Mol basis Dis. 2019;1865(9):2356–67.PubMedCrossRef
145.
Au-Yang D, Au-Zhang J, Au-Xu J, Au-Zhu T, Au-Fan Y, Au-Fan J, et al. Production of apolipoprotein C-III knockout rabbits using zinc finger nucleases. JoVE. 2013;(81):e50957.
146.
Koike T, Kitajima S, Yu Y, Li Y, Nishijima K, Liu E, et al. Expression of human apoAII in transgenic rabbits leads to dyslipidemia: a new model for combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 2009;29(12):2047–53.PubMedCrossRef
147.
Wang Y, Niimi M, Nishijima K, Waqar AB, Yu Y, Koike T, et al. Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits. Arterioscler Thromb Vasc Biol. 2013;33(2):224–31.PubMedCrossRef
148.
Song J, Wang G, Hoenerhoff MJ, Ruan J, Yang D, Zhang J, et al. Bacterial and pneumocystis infections in the lungs of gene-knockout rabbits with severe combined immunodeficiency. Front Immunol. 2018;9:429.PubMedPubMedCentralCrossRef
149.
Yang D, Liang X, Pallas B, Hoenerhoff M, Ren Z, Han R, et al. Production of CFTR-DeltaF508 Rabbits. Front Genet. 2020;11:627666.PubMedCrossRef
150.
151.
Nath AP, Ritchie SC, Byars SG, Fearnley LG, Havulinna AS, Joensuu A, et al. An interaction map of circulating metabolites, immune gene networks, and their genetic regulation. Genome Biol. 2017;18(1):146.PubMedPubMedCentralCrossRef
152.
Chouchani ET, Pell VR, Gaude E, Aksentijevic D, Sundier SY, Robb EL, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature. 2014;515(7527):431–5.PubMedPubMedCentralCrossRef
153.
Bhattacharya S, Granger CB, Craig D, Haynes C, Bain J, Stevens RD, et al. Validation of the association between a branched chain amino acid metabolite profile and extremes of coronary artery disease in patients referred for cardiac catheterization. Atherosclerosis. 2014;232(1):191–6.PubMedCrossRef
154.
Shah SH, Bain JR, Muehlbauer MJ, Stevens RD, Crosslin DR, Haynes C, et al. Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ Cardiovasc Genet. 2010;3(2):207–14.PubMedCrossRef
155.
Shah SH, Sun JL, Stevens RD, Bain JR, Muehlbauer MJ, Pieper KS, et al. Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. Am Heart J. 2012;163(5):844–50 e1.PubMedCrossRef
156.
Mittelstrass K, Ried JS, Yu Z, Krumsiek J, Gieger C, Prehn C, et al. Discovery of sexual dimorphisms in metabolic and genetic biomarkers. PLoS Genet. 2011;7(8):e1002215.PubMedPubMedCentralCrossRef
157.
Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575–84.PubMedPubMedCentralCrossRef
158.
Zhao M, Zhao L, Xiong X, He Y, Huang W, Liu Z, et al. TMAVA, a metabolite of intestinal microbes, is increased in plasma from patients with liver steatosis, inhibits gamma-Butyrobetaine hydroxylase, and exacerbates fatty liver in mice. Gastroenterology. 2020;158(8):2266–81 e27.PubMedCrossRef
159.
Rom O, Liu Y, Liu Z, Zhao Y, Wu J, Ghrayeb A, et al. Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome. Sci Transl Med. 2020;12(572):eaaz2841.
160.
Gieger C, Geistlinger L, Altmaier E, Hrabe de Angelis M, Kronenberg F, Meitinger T, et al. Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet. 2008;4(11):e1000282.PubMedPubMedCentralCrossRef
161.
Shah SH, Hauser ER, Bain JR, Muehlbauer MJ, Haynes C, Stevens RD, et al. High heritability of metabolomic profiles in families burdened with premature cardiovascular disease. Mol Syst Biol. 2009;5:258.PubMedPubMedCentralCrossRef
162.
Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518(7538):197–206.PubMedPubMedCentralCrossRef
163.
Cheng S, Shah SH, Corwin EJ, Fiehn O, Fitzgerald RL, Gerszten RE, et al. Potential impact and study considerations of metabolomics in cardiovascular health and disease: a scientific statement from the American Heart Association. Circ Cardiovasc Genet. 2017;10(2):e000032.PubMedPubMedCentralCrossRef
164.
Demirkan A, Henneman P, Verhoeven A, Dharuri H, Amin N, van Klinken JB, et al. Insight in genome-wide association of metabolite quantitative traits by exome sequence analyses. PLoS Genet. 2015;11(1):e1004835.PubMedPubMedCentralCrossRef
165.
Hong MG, Karlsson R, Magnusson PK, Lewis MR, Isaacs W, Zheng LS, et al. A genome-wide assessment of variability in human serum metabolism. Hum Mutat. 2013;34(3):515–24.PubMedCrossRef
166.
Kwok MK, Kawachi I, Rehkopf D, Schooling CM. The role of cortisol in ischemic heart disease, ischemic stroke, type 2 diabetes, and cardiovascular disease risk factors: a bi-directional Mendelian randomization study. BMC Med. 2020;18(1):363.PubMedPubMedCentralCrossRef
167.
Feofanova EV, Chen H, Dai Y, Jia P, Grove ML, Morrison AC, et al. A genome-wide association study discovers 46 loci of the human metabolome in the hispanic community health study/study of Latinos. Am J Hum Genet. 2020;107(5):849–63.PubMedPubMedCentralCrossRef
168.
Jones GT, Marsman J, Bhat B, Phillips VL, Chatterjee A, Rodger EJ, et al. DNA methylation profiling identifies a high effect genetic variant for lipoprotein(a) levels. Epigenetics. 2020;15(9):949–58.PubMedPubMedCentralCrossRef
169.
Karjalainen MK, Holmes MV, Wang Q, Anufrieva O, Kahonen M, Lehtimaki T, et al. Apolipoprotein A-I concentrations and risk of coronary artery disease: a Mendelian randomization study. Atherosclerosis. 2020;299:56–63.PubMedCrossRef
170.
Tabassum R, Ramo JT, Ripatti P, Koskela JT, Kurki M, Karjalainen J, et al. Genetic architecture of human plasma lipidome and its link to cardiovascular disease. Nat Commun. 2019;10(1):4329.PubMedPubMedCentralCrossRef
171.
172.
Braun KVE, Dhana K, de Vries PS, Voortman T, van Meurs JBJ, Uitterlinden AG, et al. Epigenome-wide association study (EWAS) on lipids: the Rotterdam Study. Clin Epigenetics. 2017;9:15.PubMedPubMedCentralCrossRef
173.
Nuotio ML, Pervjakova N, Joensuu A, Karhunen V, Hiekkalinna T, Milani L, et al. An epigenome-wide association study of metabolic syndrome and its components. Sci Rep. 2020;10(1):20567.PubMedPubMedCentralCrossRef
174.
Chitrala KN, Hernandez DG, Nalls MA, Mode NA, Zonderman AB, Ezike N, et al. Race-specific alterations in DNA methylation among middle-aged African Americans and Whites with metabolic syndrome. Epigenetics. 2020;15(5):462–82.PubMedCrossRef
175.
Soriano-Tarraga C, Lazcano U, Giralt-Steinhauer E, Avellaneda-Gomez C, Ois A, Rodriguez-Campello A, et al. Identification of 20 novel loci associated with ischaemic stroke. Epigenome-wide association study. Epigenetics. 2020;15(9):988–97.PubMedPubMedCentralCrossRef
176.
Kazmi N, Elliott HR, Burrows K, Tillin T, Hughes AD, Chaturvedi N, et al. Associations between high blood pressure and DNA methylation. PLoS One. 2020;15(1):e0227728.PubMedPubMedCentralCrossRef
177.
Meder B, Haas J, Sedaghat-Hamedani F, Kayvanpour E, Frese K, Lai A, et al. Epigenome-wide association study identifies cardiac gene patterning and a novel class of biomarkers for heart failure. Circulation. 2017;136(16):1528–44.PubMedCrossRef
178.
179.
Ryer EJ, Ronning KE, Erdman R, Schworer CM, Elmore JR, Peeler TC, et al. The potential role of DNA methylation in abdominal aortic aneurysms. Int J Mol Sci. 2015;16(5):11259–75.PubMedPubMedCentralCrossRef
180.
Agha G, Mendelson MM, Ward-Caviness CK, Joehanes R, Huan T, Gondalia R, et al. Blood leukocyte DNA methylation predicts risk of future myocardial infarction and coronary heart disease. Circulation. 2019;140(8):645–57.PubMedPubMedCentralCrossRef
181.
Wang B, Lunetta KL, Dupuis J, Lubitz SA, Trinquart L, Yao L, et al. Integrative omics approach to identifying genes associated with atrial fibrillation. Circ Res. 2020;126(3):350–60.PubMedCrossRef
182.
Vineis P, Khan AE, Vlaanderen J, Vermeulen R. The impact of new research technologies on our understanding of environmental causes of disease: the concept of clinical vulnerability. Environ Health. 2009;8:54.PubMedPubMedCentralCrossRef
183.
Metadata
Title
Integration of Transformative Platforms for the Discovery of Causative Genes in Cardiovascular Diseases
Authors
Haocheng Lu
Jifeng Zhang
Y. Eugene Chen
Minerva T. Garcia-Barrio
Publication date
01-06-2021
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 3/2021
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-021-07175-1

Other articles of this Issue 3/2021

Cardiovascular Drugs and Therapy 3/2021 Go to the issue

Invited Review Article

Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction

Invited Review Article

The Interface of Therapeutics and Genomics in Cardiovascular Medicine

Review Article

The Potential of Albuminuria as a Biomarker of Diabetic Complications

Review Article

Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention in Patients with Left Ventricular Systolic Dysfunction

Original Article

Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases

Review Article

Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits